Bretylium

• Adrenergic Antagonists
• Anti-Arrhythmia Agents
• Antihypertensive Agents
• ATC:C01BD02

• Bretylan
• Bretylate
• Bretylium Tosylate
• Bretylium Tosylate In Dextrose 5%
• Bretylium Tosylate In Plastic Container
• Bretylium p-toluenesulfonate
• Bretylium tolsylate
• Bretylol
• Bretylum
• Darenthin
• Darentin
• Ornid

• No information avaliable

C₁₁H₁₇BrN+

http://www.rxlist.com/cgi/generic3/bretosy.htm

Bretylium MSDS

No information avaliable

243.163 g/mol

No information avaliable

Freely soluble

Solid

No information avaliable

Solution for injection (50mg/mL)

For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.

Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.

No information avaliable

Oral, mouse: LD₅₀ = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.

Humans and other mammals